Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

Earlier we have shown the expression of a constitutively active receptor tyrosine kinase Axl in CLL B-cells from previously untreated CLL patients, and that Axl inhibitor TP-0903 induces robust leukemic B-cell death. To explore whether Axl is an effective target in relapsed/refractory CLL patients,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Sinha, Sutapa, Boysen, Justin C., Chaffee, Kari G., Kabat, Brian F., Slager, Susan L., Parikh, Sameer A., Secreto, Charla R., Call, Tim, Shanafelt, Tait D., Leis, Jose F., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324680/
https://ncbi.nlm.nih.gov/pubmed/30647852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26444
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi